#BEGIN_DRUGCARD DB03979

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C39H75O10P

# Chemical_IUPAC_Name:
[(2S)-2,3-dihydroxypropoxy][(2S)-3-(hexadecanoyloxy)-2-({8-[(1R,2R)-2-hexylcyclopropyl]octanoyl}oxy)propoxy]phosphinic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
1-[Glycerolylphosphonyl]-2-[8-(2-Hexyl-Cyclopropyl)-Octanal-1-Yl]-3-[Hexadecanal-1-Yl]-Glycerol

# HET_ID:
DGG

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C39H75O10P/c1-3-5-7-9-10-11-12-13-14-15-16-19-23-27-38(42)46-32-37(33-48-50(44,45)47-31-36(41)30-40)49-39(43)28-24-20-17-18-22-26-35-29-34(35)25-21-8-6-4-2/h34-37,40-41H,3-33H2,1-2H3,(H,44,45)/t34-,35-,36+,37+/m1/s1

# InChI_Key:
InChIKey=JWIOKCJPLNKYBQ-MDOFDWFASA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
3979

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
734.9806

# Molecular_Weight_Mono:
734.509785132

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1CQX

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
7.7

# Predicted_LogS:
-6.8

# Predicted_Water_Solubility:
1.27e-04 g/l

# Primary_Accession_No:
DB03979

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
46936853

# PubChem_Substance_ID:
46507734

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT01177

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CCCCCCCCCCCCCCCC(=O)OC[C@@H](CO[P@](O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCC[C@@H]1C[C@H]1CCCCCC

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:22:49 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cytoplasm

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
X74334

# Drug_Target_1_GenBank_ID_Protein:
460999

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
hmp

# Drug_Target_1_Gene_Sequence:
>1212 bp
ATGCTGACCCAGAAAACAAAAGACATCGTAAAGGCCACCGCACCGGTGCTGGCCGAACAC
GGCTACGACATCATCAAGTGCTTCTATCAGCGCATGTTCGAAGCGCATCCCGAACTGAAG
AATGTGTTCAACATGGCCCACCAGGAACAGGGCCAGCAGCAGCAGGCGCTGGCACGGGCG
GTCTATGCCTATGCGGAGAATATCGAGGACCCAAACAGTCTGATGGCCGTCCTGAAGAAC
ATCGCCAACAAGCATGCAAGTCTCGGCGTCAAACCGGAACAGTACCCCATTGTTGGAGAA
CACCTACTGGCCGCCATCAAGGAAGTGTTGGGCAATGCCGCAACCGACGACATCATTTCC
GCTTGGGCGCAAGCCTACGGGAATCTGGCCGATGTCCTGATGGGCATGGAGAGCGAGTTG
TATGAGCGCTCTGCGGAACAACCCGGTGGCTGGAAGGGGTGGCGCACCTTTGTGATTCGT
GAGAAGCGCCCCGAGAGCGATGTGATCACGTCATTCATCCTTGAGCCTGCCGATGGTGGT
CCCGTGGTGAACTTCGAACCCGGACAATACACCAGCGTCGCAATCGATGTGCCCGCGCTC
GGGTTGCAGCAGATTCGCCAATACAGCCTGTCGGATATGCCGAACGGGCGCACGTATCGC
ATCTCGGTGAAGCGCGAGGGCGGCGGGCCGCAGCCTCCGGGCTATGTTTCGAACCTGTTG
CATGATCACGTGAATGTTGGGGATCAGGTCAAGCTGGCTGCGCCCTATGGAAGCTTCCAT
ATCGACGTTGACGCCAAGACACCCATTGTCCTGATCAGCGGTGGCGTTGGGCTGACACCG
ATGGTCAGCATGCTCAAAGTGGCATTGCAGGCCCCACCGAGGCAAGTTGTATTCGTGCAT
GGCGCACGTAACAGCGCAGTACACGCGATGCGCGACAGGCTGCGCGAAGCGGCGAAGACC
TATGAAAACCTTGACCTCTTTGTTTTCTATGACCAACCGCTACCGGAAGATGTCCAGGGA
CGGGACTATGATTATCCGGGCTTAGTCGATGTGAAGCAGATCGAGAAATCGATCCTGCTG
CCAGACGCCGACTACTACATCTGCGGTCCGATTCCGTTCATGCGAATGCAGCATGATGCC
CTGAAGAATCTCGGCATTCATGAGGCACGCATTCATTACGAAGTGTTTGGTCCCGACCTG
TTTGCTGAGTAG

# Drug_Target_1_General_Function:
Energy production and conversion

# Drug_Target_1_General_References:
10336624	Ollesch G, Kaunzinger A, Juchelka D, Schubert-Zsilavecz M, Ermler U: Phospholipid bound to the flavohemoprotein from Alcaligenes eutrophus. Eur J Biochem. 1999 Jun;262(2):396-405.
12948488	Schwartz E, Henne A, Cramm R, Eitinger T, Friedrich B, Gottschalk G: Complete nucleotide sequence of pHG1: a Ralstonia eutropha H16 megaplasmid encoding key enzymes of H(2)-based ithoautotrophy and anaerobiosis. J Mol Biol. 2003 Sep 12;332(2):369-83.
1594608	Zhu H, Riggs AF: Yeast flavohemoglobin is an ancient protein related to globins and a reductase family. Proc Natl Acad Sci U S A. 1992 Jun 1;89(11):5015-9.
8125952	Cramm R, Siddiqui RA, Friedrich B: Primary sequence and evidence for a physiological function of the flavohemoprotein of Alcaligenes eutrophus. J Biol Chem. 1994 Mar 11;269(10):7349-54.
8557026	Ermler U, Siddiqui RA, Cramm R, Friedrich B: Crystal structure of the flavohemoglobin from Alcaligenes eutrophus at 1.75 A resolution. EMBO J. 1995 Dec 15;14(24):6067-77.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
3102

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
44783

# Drug_Target_1_Name:
Flavohemoprotein

# Drug_Target_1_Number_of_Residues:
403

# Drug_Target_1_PDB_ID:
1CQX

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00042	Globin
PF00175	NAD_binding_1
PF00970	FAD_binding_6

# Drug_Target_1_Protein_Sequence:
>Flavohemoprotein
MLTQKTKDIVKATAPVLAEHGYDIIKCFYQRMFEAHPELKNVFNMAHQEQGQQQQALARA
VYAYAENIEDPNSLMAVLKNIANKHASLGVKPEQYPIVGEHLLAAIKEVLGNAATDDIIS
AWAQAYGNLADVLMGMESELYERSAEQPGGWKGWRTFVIREKRPESDVITSFILEPADGG
PVVNFEPGQYTSVAIDVPALGLQQIRQYSLSDMPNGRSYRISVKREGGGPQPPGYVSNLL
HDHVNVGDQVKLAAPYGSFHIDVDAKTPIVLISGGVGLTPMVSMLKVALQAPPRQVVFVH
GARNSAVHAMRDRLREAAKTYENLDLFVFYDQPLPEDVQGRDYDYPGLVDVKQIEKSILL
PDADYYICGPIPFMRMQHDALKNLGIHEARIHYEVFGPDLFAE

# Drug_Target_1_Reaction:
2 nitric oxide + 2 O2 + NAD(P)H = 2 nitrate + NAD(P)+ + H+

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
In the presence of oxygen and NADH, FHP has NADH oxidase activity, which leads to the generation of superoxide and H(2)O(2), both in vitro and in vivo, and it has been suggested that FHP might act as an amplifier of superoxide stress. Under anaerobic conditions, FHP also exhibits nitric oxide reductase and FAD reductase activities. However, all these reactions are much lower than NOD activity

# Drug_Target_1_SwissProt_ID:
P39662

# Drug_Target_1_SwissProt_Name:
HMP_CUPNH

# Drug_Target_1_Synonyms:
EC 1.14.12.17
FHP
Flavohemoglobin
Hemoglobin-like protein
NO oxygenase
NOD
Nitric oxide dioxygenase

# Drug_Target_1_Theoretical_pI:
5.57

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB03979
